Sugi Predict

Sugi Predict / Compounds / SCHEMBL658301

SCHEMBL658301

SCHEMBL658301

O=C1Cc2cnccc2N1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE3B Q13370 2/20 0.59
▸ PDE3A Q14432 2/20 0.59
▸ CYP1A2 P05177 2/20 0.55
▸ CYP11B1 P15538 2/20 0.55
▸ CYP11B2 P19099 2/20 0.55
▸ AHR P35869 4/20 0.53
▸ PDK2 Q15119 1/20 0.53
▸ KDR P35968 4/20 0.45
▸ PLK1 P53350 3/20 0.45
▸ CMA1 P23946 2/20 0.43
▸ CYP2C9 P11712 1/20 0.43
▸ TBXAS1 P24557 1/20 0.43
▸ GSK3A P49840 4/20 0.43
▸ GSK3B P49841 4/20 0.43
▸ CDK5 Q00535 4/20 0.42
▸ CDK5R1 Q15078 4/20 0.42
▸ CCNT1 O60563 1/20 0.42
▸ CCNT2 O60583 1/20 0.42
▸ CCNB2 O95067 1/20 0.42
▸ CDK1 P06493 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL15650437 0.98 PDE3B (0.57) PDE3BPDE3ACYP1A2CYP11B1CYP11B2
SCHEMBL477609 0.84 PDE3B (0.54) PDE3BPDE3ACYP1A2CYP11B1CYP11B2
SCHEMBL29526300 0.84 PDE3B (0.54) PDE3BPDE3ACYP1A2CYP11B1CYP11B2
SCHEMBL3462883 0.82 CYP11B1 (0.56) PDE3BPDE3ACYP1A2CYP11B1CYP11B2
Hydrochloric Acid SCHEMBL2362200 0.82 PDE3B (0.53) PDE3BPDE3ACYP1A2CYP11B1CYP11B2
SCHEMBL7015184 0.79 MAPT (0.58) PDE3BPDE3ACYP1A2CYP11B1CYP11B2
SCHEMBL19553105 0.79 PDE3B (0.42) PDE3BPDE3ACYP1A2CYP11B1CYP11B2
SCHEMBL5387552 0.77 TDP2 (0.57) PDE3BPDE3ATDP2
SCHEMBL4595981 0.77 GSK3B (0.50) PDE3BPDE3ACYP1A2CYP11B1CYP11B2
SCHEMBL3313252 0.74 CYP11B1 (0.56) PDE3BPDE3ACYP1A2CYP11B1CYP11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 240 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250320224-A1 NOVEL PAR-2 INHIBITORS DOMAIN THERAPEUTICS (FR) 2025-10-16 — — US claimed
CN-119384420-A Novel PAR-2 inhibitors 多曼治疗学公司 2025-01-28 — — CN claimed
EP-4743078-A2 APOL1 INHIBITORS AND METHODS OF USE Maze Therapeutics, Inc. (US) 2026-05-20 — — EP disclosed
EP-4735420-A1 ARYL INDOL-3-YL KETONE AND ARYL INDAZOL-3-YL KETONE INHIBITORS OF KIF18A Volastra Therapeutics, Inc. (US) 2026-05-06 — — EP disclosed
EP-4727548-A1 METHOD OF TREATING CANCER WITH INDOLINE INHIBITORS OF KIF18A Volastra Therapeutics, Inc. (US) 2026-04-22 — — EP disclosed
US-20260098018-A1 BICYCLIC 1,4-DIAZEPANONES AND THERAPEUTIC USES THEREOF CYTOKINETICS INC (US) 2026-04-09 — — US disclosed
US-20250368654-A1 HETEROCYCLIC INHIBITORS OF ENPP1 VOLASTRA THERAPEUTICS, INC. (US) 2025-12-04 — — US disclosed
WO-2025235367-A1 AZAINDOLINONE COMPOUNDS AS KCA3.1 POTASSIUM CHANNEL BLOCKERS D. E. SHAW RESEARCH, LLC (US) 2025-11-13 — — WO disclosed
EP-4638433-A1 NAMPT MODULATORS Cytokinetics, Inc. (US) 2025-10-29 — — EP disclosed
US-20250320224-A1 NOVEL PAR-2 INHIBITORS DOMAIN THERAPEUTICS (FR) 2025-10-16 — — US disclosed
US-12441691-B2 Bicyclic 1,4-diazepanones and therapeutic uses thereof CYTOKINETICS, INC. (US) 2025-10-14 — — US disclosed
WO-2012098132-A1 NOVEL 4-AMINO-N-HYDROXY-BENZAMIDES AS HDAC INHIBITORS FOR THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2012-07-26 — — WO disclosed
US-8138168-B1 Renin inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-20 — — US disclosed
WO-2012022707-A1 SUBSTITUTED HETEROARYL SPIROPYRROLIDINE MDM2 ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2012-02-23 — — WO disclosed
US-20120046306-A1 Substituted Heteroaryl Spiropyrrolidine MDM2 Antagonists BARTKOVITZ DAVID JOSEPH (US) 2012-02-23 — — US disclosed
EP-1180105-A2 SUBSTITUTED AZA-OXINDOLE DERIVATIVES GLAXO GROUP LIMITED (GB) 2002-02-20 — — EP disclosed
WO-2000055159-A2 SUBSTITUTED AZA-OXINDOLE DERIVATIVES GLAXO GROUP LIMITED (GB) 2000-09-21 — — WO disclosed
US-5811432-A Azaoxindole derivatives PFIZER INC (US) 1998-09-22 — — US disclosed
WO-1991009598-A1 AZAOXINDOLE DERIVATIVES PFIZER INC. (US) 1991-07-11 — — WO disclosed
EP-0436333-A2 Azaoxindole derivatives PFIZER INC. (US) 1991-07-10 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250320224-A1 NOVEL PAR-2 INHIBITORS F2RL1, F2R, F2RL3 PDE3B 1337/4885PDE3A 1634/4885CYP1A2 181/4885
US-12441691-B2 Bicyclic 1,4-diazepanones and therapeutic uses thereof MYLK2, MUSK, MYLK PDE3B 1303/4885PDE3A 1074/4885CYP1A2 1201/4885
US-20250368654-A1 HETEROCYCLIC INHIBITORS OF ENPP1 ENPP1, ENPP3, ENPP2 PDE3B 103/4885PDE3A 99/4885CYP1A2 3574/4885
US-20260098018-A1 BICYCLIC 1,4-DIAZEPANONES AND THERAPEUTIC USES THEREOF MYLK2, TNNT2, RYR1 PDE3B 858/4885PDE3A 590/4885CYP1A2 1144/4885
US-20120046306-A1 Substituted Heteroaryl Spiropyrrolidine MDM2 Antagonists MDM2, TP53, RB1 PDE3B 4373/4885PDE3A 4328/4885CYP1A2 1437/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.